Author:
Ariake Kyohei,Motoi Fuyuhiko,Mizuma Masamichi,Ohtsuka Hideo,Hayashi Hiroki,Nakagawa Kei,Hata Tatsuo,Mitachi Katsutaka,Naitoh Takeshi,Kamei Takashi,Unno Michiaki
Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936–45.
2. National Comprehensive Cancer Network. NCCN guidelines version.018 pancreatic adenocarcinoma.
https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
.
3. Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, et al. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer. 2008;99:760–7.
4. Tanigawa N, Yamaue H, Ohyama S, Sakuramoto S, Inada T, Kodera Y, et al. Exploratory phase ii trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). Gastric Cancer. 2016;19:350–60.
5. Mekata E, Sonoda H, Shimizu T, Tatsuta T, Yamaguchi T, Endo Y, et al. Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stages II–III colorectal cancer. Mol Clin Oncol. 2013;1:763–7.